Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of AZD5363 in advanced solid malignancies
NL-OMON43802Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of capivasertib in Nonhematologic neoplasms, breast cancer and gynecological cancer (6 arms), sponsored by AstraZeneca. Primary endpoint: Safety and tolerability. Started Dec 2010; status: completed.
02
Drugs
capivasertib
03
Conditions
Nonhematologic neoplasmsbreast cancergynecological cancer
Beyond the preview
Go deeper on NL-OMON43802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43802.